Abstract. S-adenosyl methionine dependent methyltransferases are ubiquitous in nature, methylating a vast range of small molecule metabolites, as well as biopolymers. This review covers the recent advances in the development of methyltransferase enzymes for synthetic applications, focusing on the methyltransferase catalysed transformations with S-adenosyl methionine analogs, as well as non-native substrates. We discuss how researchers have used metabolic engineering approaches to enhance S-adenosyl methionine production in vivo. Enzymatic approaches that enable the more efficient generation of S-adenosyl methionine analogs, including more stable analogs, will also be described; this has expanded the biocatalytic repertoire of methyltransferases from methylation to a broader range of alkylation reactions. The review also examines how the selectivity of the methyltransferase enzymes can be improved through structure guided mutagenesis approaches. Finally we will discuss how methyltransferases can be deployed in multi-enzyme cascade reactions and suggest future challenges and avenues for further investigation.
there has been interest in exploiting the selectivity and benign operating conditions of MTases for synthetic applications, including the derivatization of non-native substrates. For example, in synthetic chemistry, methyl substituents are often introduced to optimize lipophilicity, binding affinity and other properties in the development of pharmaceuticals. [4] However, the commonly used synthetic (non-enzymatic) alkylating agents are toxic and do not usually afford good regio-, chemo-or stereo-selectivity, which makes cleaner and more selective biocatalytic methylation approaches particularly attractive.
Many MTases have also been shown to accept AdoMet analogs (e.g. 1b-m, Figure 1A ) with alternative, S-alkyl substituents, facilitating the transfer of a range of functional groups to acceptor substrates. [2, 3, [5] [6] [7] [8] [9] [10] Moreover, the transfer of an orthogonally reactive functional group from an AdoMet analog (e.g. 1j-m, Figure 1A ) to proteins or nucleic acid substrates has found application as a biomolecular labelling tool. [7, [11] [12] [13] [14] Nevertheless, the production and recycling of AdoMet (1a) and AdoMet analogs remains a challenge. The development of MTases as biocatalysts for transformations of non-native substrates is also an area of interest. In this review, we will focus on recent research to generate AdoMet analogs, as well as the characterization and engineering of new MTase biocatalysts. [3, 15, 16] This review will also describe new cascade reactions that include MTases. [17, 12] For earlier work in this field, the reader is referred to the previous review by Struck et al, which describes research on MTases prior to 2012. [18] Co-factor generation. One of the main limitations of utilizing MTases in vitro is the availability of AdoMet (1a). To date, no effective in vitro AdoMet recycling system has been developed. In light of this, the deployment of MTases for larger scale methylation reactions is most viable in vivo. For example, a mammalian catechol O-methyl transferase (COMT) has been used to produce vanillin (a commercially important fine chemical) in engineered strains of yeast or E. coli. [19, 20] The deregulation of AdoMet biosynthesis in E. coli has been shown to increase levels of AdoMet and improve yields of vanillin. [19] The production of AdoMet was upregulated via the over expression of methionine biosynthetic genes and the deletion of the transcriptional repressor (metJ), which normally regulates methionine production. [19] Metabolic engineering approaches could provide valuable engineered host strains, with elevated AdoMet production, for expression of other MTases.
A wide range of MTases can utilize AdoMet analogs with alternative substituents in place of the S-methyl group (e.g. 1b-m, Figure 1A ). The early studies utilized AdoMet analogs that were prepared synthetically via alkylation of S-adenosyl-L-homocysteine (AdoHcy, 2) [14, 21] However, the synthetic approach results in a mixture of sulfonium epimers, which require separation as only the (S)-configured diastereoisomer is normally accepted by MTases and the opposite (R)-diastereoisomer, along with residual AdoHcy (2) can inhibit MTases. [3] More recently, enzymatic approaches have been developed to produce AdoMet analogs, which overcome some of the difficulties associated with the synthetic method ( Figure 1A ). For example, the halogenase enzymes SalL from Salinispora tropica [22] and 5ʹ-fluoro-5ʹ-deoxyadenosine synthase (FDAS) from
Streptomyces cattleya [23] , which cleave AdoMet to give L-methionine (L-Met) and 5´-chloro or 5´-fluoro-5´deoxyadenosine (ClDA 3 or FDA 4) respectively, can be utilised in the reverse direction to produce AdoMet or AdoMet analogs from the corresponding L-Met (5a) or L-Met derivative (5b-m, Figure 1A ). [15, 24] The use of halogenases and MAT offers several advantages over synthetic methods for producing AdoMet analogs. The enzymatic approaches enable the efficient and selective production of the single active sulfonium (or selenonium) diastereomer in situ, with good yields, obviating the need for co-factor purification steps prior to MTase catalysed alkylation reactions. The ability to couple enzymatic co-factor generation with subsequent MTase biocatalysis is also particularly important given the instability of AdoMet (analogs) under typical enzymatic reaction conditions. [1] AdoMet spontaneously decomposes in buffers at physiological pH and ambient temperatures with a relatively short half-life (t 1/2 = 17 ± 0.4 h), whilst some AdoMet analogs are even more susceptible to rapid degradation. [27] The two main AdoMet degradation pathways are side chain cyclisation, which generates 5´-deoxy-5´-methylthioadenosine (MTA, 6) that can inhibit MTases, and depurination to give S-pentosylmethionine (7, Figure 1B ). To overcome co-factor degradation, three
AdoMet isosteres (8-10) with increased stability were prepared enzymatically using hMAT2A ( Figure   1B ) and all were shown to be functional as cofactors, in methylation reactions with a prototypical Class I MTase (DnrK). [28] Notably the 7dzAdotMet (10) The methylated product celesticetin (11) is a lincosamide antibiotic with N-methylation proving vital for its activity. Recently, the crystal structure of Ccbj was solved by Bauer et al who identified three key residues in this N-MTase, Y9 (catalytic base), Y17 and F117 (substrate binding residues), as well as a large substrate binding site ( Figure 2B ). [30] It is envisaged that the large and potentially promiscuous substrate binding site of Ccbj could enable future studies to generate a library of clinically important N-methyl lincosamide antibiotics. [29, 30] BamL from Bacillus amyloliquefaciens dimethylates an N-terminal amino group of thiazole/oxazole modified peptide precursor in the biosynthesis of plantazolicin (Figure 2A ). [31] Again the activity of plantazolicin is drastically reduced without the N-methylation. Structural studies identified BamL to have a catalytic base (Y182), and a narrow substrate channel, which accounts for its limited substrate range ( Figure 2B ). Initial studies investigated whether the plantazolicin mimic bradykinin could be a potential substrate, but this proved unsuccessful.
However, with structural knowledge in hand, shorter synthetic tetrapeptide analogs of natural peptide (14mer) substrate were shown to be methylated by BamL and the resulting products (e.g.
12)
displayed antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA).
[ 31, 32] The crystal structures of two MTase enzymes involved in benzylisoquinoline alkaloid biosynthesis have also recently been elucidated, the pavine-N-methyltransferase (PNMT) and norcoclaurine-6-O-methyltransferase (6OMT) ( Figure 2B ). [33, 34] The characterization of MTases from these pathways could be useful in developing biocatalytic approaches for production of alkaloid derivatives, which have been widely used as pharmaceuticals. Robin et al solved the structure of 6-OMT which is known to methylate at the 6-OH position of norcoclaurine producing coclaurine (14) . [34, 35] Based on comparisons with the structurally similar O-methyltransferases (OMTases) caffeic acid-O-methyltransferase (CaOMT) and isoflavone-O-methyltransferase (IOMT), the residues F119, W123, I114, F140 and F162 of 6-OMT were determined to be important for substrate specificity. [34] Hence, mutagenesis of these key residues may lead to an expanded substrate range.
Another structurally similar O-MTase, PAMTH1, from the plant Podospora anserine, methylates the isoflavone myricetin. [36, 37] This enzyme may provide access to a range of methylated flavonoids (15) , which have been shown to have anti-inflammatory and anti-cancer properties.
[38] The improved structural understanding of both O-MTase and N-MTase active sites can now be used to expand the substrate range of these enzymes, increasing their value as biocatalysts with non-native substrates ( Figure 2B ). [1, 12, 16, 32, 34, 36] The mammalian catechol O-methyltransferase (COMT) is involved in catabolism of catecholamines such as dopamine. The active site of COMT is close to the enzyme surface, enabling a variety of non-native catechol substrates to be methylated (16) . The substrate promiscuity of COMT has been exploited for production of vanillin. [19, 39, 40] However, COMT catalysed methylation of vanillin precursor 3,4-dihydroxybenzaldehyde (19) results in a mixture of vanillin (20) and isovanillin (21) regioisomers ( Figure 3A) . Based on the structure of the COMT active site ( Figure   3B ), Law et al conducted mutagenesis studies leading to a mutant Y200L, which improved COMT regioselectivity from 58% to 90% regioisomeric excess in favour of the desired meta-methylated product 20 whilst maintaining near WT activity. The improved regioselectivity of the Y200L mutant was also exploited to effect a one-pot tandem enzymatic synthesis of the commercially important fine chemical ethyl vanillin in a 58% isolated with ethyl-AdoMet (1b) generated in situ ( Figure 1A ). respectively, of rapamycin precursors in Streptomyces rapamycinicus [43] . In recent studies, the recombinant RapM enzyme was shown to selectively methylate desmethyl rapamycin precursors at the 16-OH position (17, Figure 2A ) [1] . Moreover RapM was shown to accept AdoMet derivatives, transferring alternative substituents to the 16-OH position [1] . Similar approaches have also been used in the alkyl diversification of other bioactive natural product scaffolds, [2, 3] providing strategies for generating natural product derivatives with altered physicochemical properties and bioactivity, or installing orthogonal handles to pull down in vivo biological targets (binding partners). [1] [2] [3] The alkyl diversification approach [17, [44] [45] [46] Many synthetic peptidomimetics and other pharmaceuticals are derived from β-methyl-α-amino acid building blocks, which are currently prepared using expensive multi-step synthetic processes. It is envisaged that the α-ketoacid C-MTases could be used in combination with aminotransferases to provide a more efficient and cleaner route to β-methyl-α-amino acids and derivatives. Recently Zou et al solved the X-ray crystal structure of an α-ketoacid C-MTase,from the mannopeptimycin producer Streptomyces hygroscopicus NRRL 30439 [47] . This C-MTase, phenylpyruvate-C3-methyltransferase (MppJ), methylates phenylpyruvate to generate (3R)-3-methylphenylpyruvic acid (18, Figure 2A ) which can be converted to the (2S, 3R)-3-methylphenylalanine using an aminotransferase enzyme. The MppJ structure reveals a unique non-haem iron centre that binds to and activates the α-ketoacid substrate for stereoselective methylation.
These structural insights can help guide the engineering of the other non-haem iron dependent α-ketoacid C-MTase, [47] which can enable the biocatalytic production of a wide range of β-methyl-α-amino acid building blocks. Moreover, the MppJ structure also guided mutagenesis studies leading to MppJ variants with O-MTase activity. [47] Conclusions and Future Perspectives. Despite the substantial progress in AdoMet-dependent MTase biocatalysis, the high cost of AdoMet and feedback inhibition caused by cofactor by-products, such as AdoHyc (2) MTase reactions. [6, 9] Expanding the range of chemical moieties that MTases can transfer would undoubtedly improve the versatility of this enzyme class. Several MTases accept AdoMet analogs with alternative functional groups in place of the S-methyl group; [18] however activity decreases considerably towards more bulky analogs. [14] This prompted MTase protein engineering studies focused on accommodating larger analogs with downstream applications for profiling protein methylation. [7, 8, 11, 13, 53] Moreover, an MTase which is more selective for AdoMet analogs, over AdoMet, would be desirable for in vivo or whole cell biotransformations, where analogs must outcompete the native cofactor (the cellular concentration of AdoMet in E.coli is ca. 180 µM). [10, 55] As demonstrated in this review, AdoMet-dependent MTases show significant and expanding scope for biocatalytic applications, with most recent progress in enzymatic AdoMet analog synthesis, the development of valuable tandem reactions and the design of stable AdoMet isosteres. [28] Structural studies have proved key in developing this field, enabling the MTase substrate scope to be assessed and guiding mutagenesis to expand the substrate range, cofactor range and even regioselectivity of this enzyme class. [13, 16] Perceived future work would further expand the range of AdoMet analogs which can be generated by MATs and also utilised by MTases, whilst retaining activity comparable to the wild-type enzyme/native cofactor reactions. Identifying a range of MTases with useful substrate targets for API generation, would also add value to the field. An
MTase-halogenase hybrid enzyme (AoiQ), for example, was recently reported to catalyse dichlorination of a diaporthin substrate followed by bis-O-methylation; such hybrid enzymes could prove valuable, considering the importance of both methylation and halogenation in modifying biological activity. [56] Finally, the development of an efficient AdoMet regeneration system would greatly increase the viability of MTase biocatalysis for larger scale and industrial applications. For the Y200L mutant and WT COMT dimer E199 is orientated away from the ac've site which disfavours para-methyla'on resul'ng predominantely in the meta-methylated product vanillin (20) . The Y200L muta'on is indicated in green, whilst blue indicates prefered substrate binding orienta'on (for meta-methyla'on leading to 20) in the Y200L mutant and WT COMT dimer. The rela've posi'ons of the ac've site residues and substrate (19) in the WT COMT monomer structure are shown in light grey. In this case E199 is orientated into the ac've site leading to an alterna've substrate binding mode that gives rise to higher levels of para-methyla'on leading to isovanillin (21) . 
